中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1349 records (took 0.054 seconds)

    Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use
    65.
    发明专利
    Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use 未知

    公开(公告)号：AU2005250429B2

    公开(公告)日：2011-03-31

    申请号：AU2005250429

    申请日：2005-05-27

    Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY

    Inventor： O'KEEFE BARRY ,  BOYD MICHAEL R ,  MORI TOSHIYUKI

    IPC: C07K14/405 ,  A61K38/17 ,  A61K47/48 ,  C07K16/14

    Abstract: An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viral polypeptide or conjugate or fusion protein thereof. Further provided are methods of inhibiting prophylactically or therapeutically a viral infection of a host.

    Adoptive immunotherapy with enhanced T lymphocyte survival
    66.
    发明专利
    Adoptive immunotherapy with enhanced T lymphocyte survival 未知

    公开(公告)号：AU2005336093B2

    公开(公告)日：2011-02-24

    申请号：AU2005336093

    申请日：2005-10-07

    Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY

    Inventor： ROSENBERG STEVEN A ,  HSU CARY ,  MORGAN RICHARD A

    IPC: C12N5/0783 ,  A61K39/00

    Abstract: The invention provides for compositions, e.g., pharmaceutical compositions, comprising a T lymphocyte, or a population thereof, expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of an immune response. The invention further provides an isolated T lymphocyte, or population thereof, expressing at least one recombinant polynucleotide encoding the cytokine, wherein the polynucleotide comprises a non-native coding sequence encoding the cytokine. Also provided is the use of such compositions and T lymphocytes, or populations thereof, for the treatment or prevention of a medical condition e.g., cancer. A method of preparing the a T lymphocyte with enhanced T cell survival is further provided herein.

    O6-alkylguanine-DNA alkyltransferase inactivators
    68.
    发明专利
    O6-alkylguanine-DNA alkyltransferase inactivators 未知

    公开(公告)号：AU2008222753A1

    公开(公告)日：2008-09-12

    申请号：AU2008222753

    申请日：2008-03-06

    Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY ,  PENN STATE RES FOUND

    Inventor： MOSCHEL ROBERT C ,  LOKTIONOVA NATALIA A ,  PAULY GARY T ,  PEGG ANTHONY E

    IPC: C07D473/18 ,  A61K31/522 ,  A61P35/00 ,  C07H15/26

    Abstract: Disclosed are prodrugs of inactivators of O6-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the &bgr;-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrugs are represented by the formula A-B-C, wherein A is a glucuronosyl residue linked through its 1-oxygen to the phenyl ring of B; B is a benzyloxycarbonyl group, optionally ring-substituted with one or more electron withdrawing groups; and C is an inactivator of AGT, e.g., a substituted or unsubstituted O6-benzylguanine or O6-benzyl-2′-deoxyguanosine. Also disclosed are additional inactivators of AGT, pharmaceutical compositions comprising an inactivator or prodrug and a pharmaceutically acceptable carrier, and a method of use of the inactivator or prodrug in enhancing the chemotherapeutic treatment of tumor cells in a mammal, e.g., a human, with an antineoplastic alkylating agent that causes cytotoxic lesions at the O6-position of guanine.

    Smoothened polypeptides and methods of use
    69.
    发明专利
    Smoothened polypeptides and methods of use 未知

    公开(公告)号：AU2007329678A1

    公开(公告)日：2008-06-12

    申请号：AU2007329678

    申请日：2007-10-30

    Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY

    Inventor： TARASOVA NADYA ,  DEAN MICHAEL ,  LOU HONG

    IPC: C07K14/705

    Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided. Methods of inhibiting proliferation of a diseased cell, treating or preventing cancer, treating a neoplasm or psoriasis, and inhibiting the expression of genes involved in the Hedgehog signaling pathway, thereby inhibiting the Hedgehog signaling pathway, are furthermore provided by the invention.

Patent Agency Ranking